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ABSTRACT 
Objective: The objective of this research was to formulate the captopril as mucoadhesive buccal films for hypertension treatment and studying the 
effect of different variables on the physical and mechanical behavior of the prepared films. 
Methods: The bucco-adhesive patches were prepared using hydroxyl propyl methyl cellulose K4 (HPMC) as film forming a polymer with secondary 
polymer included carbopol 934 and eudragit RL100. The patches were prepared by a solvent casting method and evaluated for the weight variation, 
surface pH, mechanical properties, content, uniformity, ex-vivo mucoadhesive strength, ex-vivo permeation study and drug release study. 
Results: Formula F5 containing HPMC as primary polymer with carbopol 934 as secondary polymer was chosen to be the best formulation for the 
following parameters: surface pH6.44, tensile strength (16.06), percentage elongation at break (34.14), swelling index(18.85), mucoadhesive 
strength(26.2 gm) and the folding endurance was>300 with an in vitro drug release about 94.73% during 6 h. 
Fourier transforms infrared spectroscopy (FT-IR) and differential scanning calorimetric studies (DSC) showed no interaction between the drug and 
polymers. 
Conclusion: It can be concluded that oral mucoadhesive buccal film of captopril, an antihypertensive agent can be prepared utilizing HPMC as a film 
forming a polymer with carbopol as a secondary polymer which extended the drug release through the buccal mucosa for 6 h. 
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The sites of oral mucosa are dissimilar from each other in the 
anatomical construction, drug permeation and their capability to 
hold a delivery dosage form for a definite period of time [1]. 
Though the sublingual area has a high absorption ability, good 
blood supply and high bioavailability, but it is unsuitable for the 
sustained drug administration due to the sublingual area lack 
immobile smooth muscle and washed by adequate volume of 
saliva make it suitable for a drug with short time management and 
frequent use [2, 3]. Drug delivery through the buccal mucosa is an 
innovative method for local and systemic management since the 
buccal mucosa is permeable with high blood supply and permits 
long-time retention of the dosage form [4]. Captopril is an 
antihypertensive drug used for the management of hypertension 
and heart failure through reduction of angiotensin II and an 
increase of bradykinin production [5]. Also, it has a renoprotective 
effect in the diabetic patient [6]. Furthermore, approximately 60-
75% of captopril is absorbed through the gastrointestinal tract, 
and the peak plasma concentrations are obtained through 1 h [7]. 
It has two dissociations constant pka1 (3.7) and pka2 (9.8), the 
half-life about 1-2 h [8]. Hence captopril is a suitable candidate for 
the buccal drug administration. The objective of this study 
prepared captopril as a mucoadhesive buccal film for hypertension 
treatment in order to increase bioavailability, reduce dosing 
frequency and improve patient compliance via solvent casting 
method and studying the effect of different variables on the 
physical and mechanical properties of the prepared films. 
MATERIALS AND METHODS  
Materials  
Captopril obtained from Awamedica, Iraqi company as a gift sample, 
(HPMC), carbopol and polyvinyl alcohol (PVA) were obtained from 
fine Indian chemicals. Eudragit was obtained from Rohm, GmbH, 
Weiterstdt, Germany, England. Propylene glycol (PG) was obtained 
from Evans Medical Ltd, Liverpool. All other reagents and chemicals 
used were of analytical grade. 
Instruments, equipment and apparatus  
Different instruments, apparatus and equipment, have been used in 
this study:  Digital venire caliper obtained from Shanghai (China), pH 
meter obtained from radiometer (Denmark), UV spectro-
photometers obtained from emclab gmbh (Germany), Dissolution 
type (2) apparatus obtained from Coply scientific (UK), FT-IR 
spectrophotometer obtained from Shimadzu (Japan), differential 
scanning calorimetry obtained from Shimadzu (Japan).  
Formulation of captopril mucoadhesive buccal film 
Eight formulations(F1-F8) were prepared (table 1) by a solvent casting 
method using the different percentage of polymer and each film with a 
surface area approximately four cm2 are loaded with 12.5 mg captopril. 
The PVA solution was prepared by dissolving the polymer in hot water at 
(60-100 °C) then the solution was left to cool [9]. While (HPMC) solution 
was prepared by heating 20-30% of distilled water volume with stirring 
to (80-90 °C) then HPMC was added. After that, the final volume was 
completed with cold water under stirring [10]. 
In all the formulas, the polymers were dissolved in a proper solvent 
with stirring under magnetic stirrer. Then PG as a plasticizer (30% 
of polymer weight) was added. Finally captopril powder 12.5 mg 
was added to the polymer solution. The prepared solution was left 
overnight to get rid of the air bubbles. 
Then these solutions were poured into aluminium foil (to be used as 
a backing layer) in a glass moulid of diameter 9 cm and left to dry in 
a hot air oven adjusted at 50 °C until flexible patches were obtained. 
The dried patches were divided into 2×2 cm2 diameter and then 
used for this study. 
Evaluation of captopril mucoadhesive buccal patch 
Weight variation 
Three randomly chosen patches were selected and weighed 
everyone alone using a digital balance then the mean value for each 
formulation was measured [11]. 
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Table 1: Composition of captopril mucoadhesive buccal patch 
Ingredient (mg) Formula code 
F1 F2 F3 F4 F5 F6 F7 F8 
Captopril 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
PVA 93.75 93.75 93.75      
HPMC    93.75 84.38 75 84.38 75 
Carbopol934     93.75 18.75   
Eudragit RL100       9.37 18.75 
PG 18.75 28.125 37.5 28.125 28.125 28.125 28.125 28.125 
 
Thickness 
Three patches randomly are chosen from each formulation and after 
that, the thickness was measured at five points using a digital venire 
caliper, then the average value was taken [12]. 
Folding endurance 
This test gives the idea about elasticity and flexibility of patches. It was 
determined manually by repetitively collapsing single patch at the 
same point until broken. The number of times of foldable at which the 
patch is not broken to indicate the value of folding endurance [13]. 
Surface pH 
In this test, film was allowed in contact with five ml of distilled water 
for 60 min at room temperature and then the pH measured by using 
pH meter, this done in triplicate and take the mean value [14]. 
Content uniformity 
This test was measured by dissolving the patch (2×2) cm2 in 100 ml 
phosphate buffer pH 6.8 under magnetic stirrer for 60 min, then the 
end result solution filtered, diluted with phosphate buffer and 
determined drug content by UV spectrophotometer at wavelength 
206 nm in triplicate [15]. 
Tensile strength and percentage of elongation 
Tensile strength (TS) is the maximum stress applied to a point at 
which the film breaks. Elongation is defined as a measure of the 
capacity of a patch to deform prior to failure. Tensile strength and 
percent elongation (% EB) of the patches were determined on 
tensile strength testing apparatus. Rectangular patch strips of 5×2 
cm2were fixed between the jaws of the instrument. The load on the 
strip was gradually increased to a maximum at a speed of 50 
mm/min. and the change in the length of the strips that occurred 
with increasing stress was measured. TS and (%EB) of three patches 
of each batch were measured [16]. 
Swelling index 
For determining the swelling index, the film (2×2) cm2 was weighed 
on a pre-weighted microscope slide (W0) and kept in a Petri dish 
containing 50 ml buffer solution. For one hour and at a regular 
period interval, the microscope slide was removed from Petri dish 
and reweigh again (Wt.). The mean of three determinations was 
recorded [17]. Then the swelling index was measured by using the 
following equation:  
Swelling index = (Wt-W0)/W0 × 100 (1) 
Where W0 is the weight of the patch before dipping into a phosphate 
buffer solution pH 6.8, Wt. is the weight of the patch after dipping 
into a phosphate buffer solution pH 6.8. 
Ex-vivo mucoadhesive strength 
A modified physical balance (locally assembled) was utilised for 
measuring the mucoadhesive strength. The fresh chicken pouch was 
used as a model (taken from the slaughter house and must use 
during 120 min since slaughter) [18]. The pouch was washed with 
phosphate buffer solution, pH 6.8 and attached at the bottom of the 
Petri dish by the help of cyanoacrylate glue; a glass stopper is 
hanged by threads at equal space from the left-hand pan. To the 
lower end of the glass stopper, the film was attached by 
cyanoacrylate gum just above the pouch membrane. The right pan 
holds an empty beaker; the two pans must balance by the addition of 
a proper weight, after that a five-gram weight is removed from the 
right pan, in order to make the film in contact with pouch 
membrane. The balance was leaved in this situation for five minutes. 
Then distilled water was slowly added to the empty beaker until the 
film separate from the chicken pouch. The weight required to 
separate the film from the chicken pouch represents the 
measurement of mucoadhesive strength [19,20].  
The forces of adhesion and bond strength were calculated using 
following equations:  
Force of adhesion (N) = Mucoadhesion strength/1000 × 9.81 (2) 
Bond strength (N/M2) = Force of adhesion (N)/Surface area (M2) (3) 
In vitro release study 
All the prepared captopril buccal patches were measured using a 
dissolution apparatus, adjusted at 37 °C, rotate at 50rpm and the 
dissolution jar filled with a 500 ml phosphate buffer solution pH 6.8 
[21]. In order to produce a unidirectional drug release, the patch 
(2×2) cm2 was placed upon glass slide by the help of cyanoacrylate 
glue, then the slide immersed in the dissolution apparatus jar. 
Aliquots of five ml sample were taken from the jar at regular time 
period (15, 30, 60, 120, 180, 240, 300, and 360) min and replaced 
with equal volume of buffer solution since the drug is soluble. The 
sample suitably diluted and analyzed by UV spectrophotometers at 
206 nm wavelength, then the dissolution profile of captopril is 
constructed by plotting the percent of accumulative drug release 
against time. The mean of three determinations was recorded [22]. 
Drug polymer compatibility study 
Fourier transform infrared spectroscopy (FT-IR) 
Fourier transforms infrared spectroscopy was determined to find 
any physical or chemical interaction between the drug and other 
material used in the dosage form. FT-IR spectrum was performed for 
the pure captopril powder and the selected formula. Samples were 
mixed with potassium bromide and pressed to form a disc; then this 
prepared disc was investigated using FT-IR spectroscopy in the 
range 4000-40 cm-1[23]. 
Differential scanning calorimetric studies (DSC) 
Differential scanning calorimeter (DSC) was used to determine the 
loss or gained of heat, produced from physical or chemical change 
inside the sample as a function of heat. The DSC scans were 
employed for pure captopril powder, a physical mixture of polymer 
and the drug in a ratio (1:1) and for selected captopril mucoadhesive 
buccal patch. The test was carried by using a Shimadzu DSC 
apparatus with temperature range 50-300 and in a rate 10/min [24]. 
Statistical analysis 
The results of the experimental work were demonstrated as a mean 
of triplicate models (±SD) were examined in relation to the one-way 
analysis of variance (ANOVA). The differences were considered 
statistically significant when (P≤ 0.05) and non-significant at a level 
of (p>0.05). 
RESULTS AND DISCUSSION 
Physical evolution 
The average weights for all prepared formulations were uniform and 
ranged (149.04-174.18 mg), All the captopril buccal patch showed a 
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satisfactory thickness (0.225-0.330 mm) and folding endurance 
more than 300, the surface pH value (6.38-6.88), when compared to 
that pH of oral mucosa indicating that it doesn't cause an irritation 
to the buccal mucosa. 
Content uniformly 
The formulated captopril buccal patch showed the acceptable quantity 
of medicament ranged from (93.03-101.01%). This result met the 
suitable extend of content uniformly labeled in BP, which is rung from 
85% to 115%. According to that, captopril was spread consistently 
throughout the four cm2 constant area of the buccal patches. 
Effect of plasticizer concentration 
The result was shown that changing PG concentration (18.75 mg for 
F1, 28.125 mg for F2 and 37.5 mg for F3) which represent (20, 30, 
and 40%) of total polymer weight affect both (TS) and (%EB). 
Increasing plasticizer concentration caused a significant decrease 
(P<0.05) in TS and significant increase (P<0.05) in %EB, this is due 
that as the concentration of plasticizer increased this lead to loosen 
the polymer molecule network and decrease the molecule 
movement within the polymer [25]. 
So that optimization of plasticizer concentration was achieved by 
selecting (28.125 mg) of PG, which is equal to (30% of total polymer 
weight) that provided both acceptable TS and %EB. Additionally, there 
is non-significant (P>0.05) increased in swelling index as PG 
concentration increased (F1, F2, F3) as in fig. (1), this it because of the 
hygroscopic nature of PG, which leads to a reduction in force between 
the polymer molecules and increasing moisture content [26].  
 
 
Fig. 1: Swelling index of the prepared captopril mucoadhesive 
buccal patches (Results are expressed as mean, n=3) 
 
Mucoadhesive characteristics  
There was a significant increase (P<0.05) in mucoadhesive and bond 
strength as PG concentration increased because the addition of 
plasticizer agents reduced the internal stress of the patch by 
decreasing the glass transition temperature of the polymer and thus 
increasing mucoadhesion forces [27]. 
While for in vitro drug release mechanism, as the PG concentration 
increase, there is a significant increase (P<0.5) in the amount of 
captopril released from the film fig. (2), this is because the higher 
concentration of PG in the film, the larger number of plasticizer 
molecules found to produce polymer chain relaxation and 
subsequent increasing captopril release from the patch [28]. 
 
 
Fig. 2: Dissolution behavior of captopril mucoadhesive buccal 
patches (Results are expressed as mean, n=3) 
 
Effect of type of film forming polymer 
Results showed that films containing PVA (F2) significantly higher 
TS (P<0.05) and (% EB) than F4 (containing HPMC) table (2). This is 
because PVA polymer contains a larger number of chains of 
molecules and between these chains, there is a homopolar bond, 
these homopolar bonds either strong or weak according to the 
polymer type. So that the force required for homopolar bond 
breakdown and patch rupturing will differ [29]. 
Swelling index, it was seen that formulas containing PVA (F2) showed 
significant decrease (P<0.05) in swelling index than formula containing 
HPMC (F4) this is because, there is averring in polymer network 
resistance toward water molecule penetration, same observations seen 
in the mucoadhesion patch of salbutamol sulphate [30]. 
Concerning the mucoadhesive characteristics in table (3), it was 
seen that there is a significant increase (P<0.05) in mucoadhesive 
and bond strengths for formula containing HPMC than those 
containing PVA, this is due to HPMC hydrate rapidly producing 
maximum swelling at short time, which facilitated polymer chain's 
interpenetration with mucus membrane, additionally HPMC having 
higher molecular weight and viscosity than PVA, and contain both 
carboxyl and hydroxyl group necessary for mucoadhesive. 
Furthermore, drug release from F4 (483.11%) at 6 h slower than 
from F2(92.57%), this is explained by HPMC has been an extensive 
swelling character, which led to produce a thick gel barrier for drug 
diffusion [31]. 
 
Table 2: Tensile strength and percent of elongation of captopril mucoadhesive buccal patches 
Formula no. TS (MPa)* %EB* 
F1 56.32±1.23 204.12±11.23 
F2 52.20±0.89 245.40±9.17 
F3 33.01±1.02 493.25±14.34 
F4 19.50±0.54 24.06±1.12 
F5 16.06±0.87 34.14±0.94 
F6 10.15±0.43 26.80±0.86 
F7 21.15±0.27 29.06±0.55 
F8 29.90±0.78 23.13±0.1.28 
*SD standard deviation from mean. n=3 
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Table 3: Mucoadhesive characteristic of captopril mucoadhesive buccal patches 
Formula no. Mucoadhesive strength* (g) Force of adhesion (N) Bond strength (Nm-2) 
F1 5.42±0.20 0.053 132.79 
F2 6.55±0.03 0.053 132.79 
F3 7.80±0.111 0.076 191.1 
F4 21.8±0.511 0.213 543.1 
F5 26.2±0.256 0.256 641.9 
F6 30.11±0.228 0.295 737.69 
F7 19.12±0.505 0.187 468.44 
F8 16.28±0.107 0.159 398.86 
*SD standard deviation from mean. n=3 
 
Effect of polymeric blend ratio 
The addition of carbopol 934 in different ratios for the formulas F5 
and F6 results in a significantly decreased in TS (P<0.05) and 
increased in %EB as the amount of carbopol increased to produce a 
flexible and soft patch, a similar finding was observed in designing a 
buccal patch of salbutamol sulphate [32]. 
While, addition of eudragit RL 100 to HPMC in different ratios (F7-
F8) result in a significant increase in TS (P<0.05) and decrease in 
% EB, this is because of eudragit produces strong cross-linking 
which leads to increase in the strength bonds of the polymer 
chains, similar observation was found in development buccal 
patch of indomethacin [33]. 
Concerning the swelling index (fig. 1), the addition of carbopol in a 
different ratio with HPMC (F5, F6) led to significant increase in the 
swelling index (P<0.05), this is because of its water solubility allows 
it to dissolve rapidly to produce high porosity. While using eudragit 
RL100 as a secondary polymer with different concentrations results 
in a significant decrease (P<0.05) in the swelling index as the 
eudragit concentration increase, this is because of its hydrophobic 
character and limited swelling ability. While incorporation of 
carbopol into HPMC (F5, F6) result in a significant increase (P<0.05) 
in the mucoadhesive and bond strengths, this is because that 
carbopol is polyacrylic acid containing both carboxyl and hydroxyl 
group, which permits the attractive polymer interaction with mucin 
layers. 
While incorporated eudragit with HPMC (F7, F8) results in a 
significant decrease in the mucoadhesive and bond strength 
(P<0.05) as the concentration of the eudragit increase, this is 
because of absent from a proton donating carboxyl group in 
eudragit, which permit a formation of a weak hydrogen bonding 
with mucus membrane. For drug release, in polymer blend 
containing carbopol (F5, F6), there is a significant increase in drug 
release (P<0.05) as the concentration of carbopol increase fig. (2), 
this is because of the carbopol ionization at pH 6.8 environment, 
which is higher than its pKa, so that its ionization creates a negative 
charge on the polymer backbone. The Same charge of polymer and 
mucin (negative charge) lead to repulsion, increase water uptake 
and drug diffusion from the matrix [34]. 
HPMC combination with eudragit (F7, F8), there was a significant 
decrease (P<0.05) in drug release as the ratio of eudragit increased 
because of hydrophobic nature of eudragit and reduced swelling 
behavior lead to decrease a drug release from a polymer matrix. 
Drug polymer compatibility study 
Fourier transform infrared spectroscopy (FT-IR) 
The principal peaks of pure captopril and the selected formula F4 were 
shown in the table (4). The resulted values show that the peaks don’t 
shift significantly in the FT-IR spectra of the selected formula F5 in 
comparison with the pure captopril as seen in fig. 3 and 4, respectively, 
and indicating the compatibility of captopril with the additives used. 
 
Table 4: FT-IR absorption bands of captopril and the prepared patch F5 
Characteristic groups  Pure drug [35] Selected formula(F5) 
S-H stretching 2567 2565 
C=O(in COOH) 1743 1702 
C=O (in amide) 1587 1583 
C-N stretching 1227 1375 
O-H stretching 3369 3352 
CH3 bending 1471 1448 
CH3 symmetric stretching  2877 2936 
CH3 Asymmetric stretching 2980 2976 
 
 
Fig. 3: FT-IR spectrum of pure captopril 
 
Fig. 4: FT-IR spectrum of the selected formula F5 of captopril 
mucoadhesive buccal patch 
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Differential scanning calorimetric studies 
Captopril peak was clear in DSC thermogram at 111.53 °C around its 
melting point fig. (5), which indicate that captopril used in its pure 
crystalline state as compared with reference [36]. The DSC 
technique was used to give an idea about the thermal stability of the 
drug and additives. The DSC of the physical mixture of captopril, 
carbopol and HPMC give an endothermic peak at 109.43 °C fig. (6), 
which indicates there is no interaction between the drug and 
polymers used, while DSC thermogram of captopril buccal patch 
shows a complete disappearance of captopril endothermic peak fig. 



































Fig. 7: DSC of the selected formula F5 
 
CONCLUSION 
It can be concluded that formulation F5 using a combination of two 
mucoadhesive polymers HPMC and carbopol could be used to 
release captopril in buccal cavity for an extended period of time 
without the risk of mucosal irritation for hypertension treatment. 
This will enhance the patient compliance throughout reduction of 
dosing administration. 
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